Myocardial contrast echocardiography in biopsy-proven primary cardiac amyloidosis

Sahar S. Abdelmoneim, Mathieu Bernier, Diego Bellavia, Imran S. Syed, Sunil V. Mankad, Krishnaswamy Chandrasekaran, Patricia A. Pellikka, Sharon L. Mulvagh

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Cardiac vasculature is affected in 88-90% of patients with primary cardiac amyloidosis (CA). Myocardial contrast echocardiography (MCE) relies on the ultrasound detection of microbubble contrast agents that are solely confined to the intravascular space, and are therefore useful in the evaluation of flow in the microvasculature. This is the first case report describing the use of MCE during vasodilator stress to evaluate coronary flow reserve in a patient with biopsy-proven primary CA and angiographically normal coronaries. Qualitative MCE demonstrated delayed replenishment of microbubbles during peak stress; quantitative analysis was consistent with a reduction in total myocardial blood flow and reserve values. Comparative imaging modalities including strain and strain rate imaging, magnetic resonance imaging, and myocardial scintigraphy were suggestive to the diagnosis of CA. In conclusion, MCE is a method for recognition of microvascular dysfunction, and might be considered as a useful tool to augment echocardiographic assessment in the early diagnosis of CA.

Original languageEnglish (US)
Pages (from-to)338-341
Number of pages4
JournalEuropean Journal of Echocardiography
Issue number2
StatePublished - Mar 2008


  • Amyloidosis
  • Contrast
  • Echocardiography

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Myocardial contrast echocardiography in biopsy-proven primary cardiac amyloidosis'. Together they form a unique fingerprint.

Cite this